Edition:
India

Kura Oncology Inc (KURA.OQ)

KURA.OQ on NASDAQ Stock Exchange Global Select Market

15.75USD
2:29am IST
Change (% chg)

$0.20 (+1.29%)
Prev Close
$15.55
Open
$15.75
Day's High
$16.10
Day's Low
$15.60
Volume
47,882
Avg. Vol
138,251
52-wk High
$16.70
52-wk Low
$4.85

Chart for

About

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood... (more)

Overall

Beta: --
Market Cap(Mil.): $387.63
Shares Outstanding(Mil.): 27.69
Dividend: --
Yield (%): --

Financials

BRIEF-Kura Oncology files for mixed shelf offering of up to $200 mln - SEC filing‍​

* Kura Oncology Inc - files for mixed shelf offering of up to $200 million - SEC filing‍​ Source text:(http://bit.ly/2yNnKBA) Further company coverage:

10 Nov 2017

BRIEF-Kura Oncology Inc entered into amendment to its sales agreement with Cowen and Co

* Kura Oncology Inc - on Nov 9, 2017, co entered into amendment to its sales agreement, dated January 27, 2017 with Cowen and Company LLC ‍​-SEC filing

10 Nov 2017

BRIEF-Kura Oncology reports third quarter 2017 financial results

* Kura Oncology reports third quarter 2017 financial results and provides corporate update

08 Nov 2017

BRIEF-KURA ONCOLOGY ‍CONFIRMS PARTIAL RESPONSES OBSERVED IN PATIENTS WITH HRAS MUTANT HNSCC IN TRIAL

* KURA ONCOLOGY LEAD CANDIDATE TIPIFARNIB SHOWS DURABLE ANTI-TUMOR ACTIVITY IN HRAS MUTANT HEAD AND NECK CANCER IN AACR-NCI-EORTC UPDATE

27 Oct 2017

BRIEF-Kura Oncology announces positive phase 2 study for Tipifarnib in HRAS mutant head and neck cancer

* Kura Oncology announces positive phase 2 study for Tipifarnib in HRAS mutant head and neck cancer

08 Sep 2017

BRIEF-‍Great Point Partners LLC reports 5.92 percent passive stake ​in Kura Oncology Inc

* ‍Great Point Partners LLC reports 5.92 percent passive stake ​in Kura Oncology Inc as on August 11, 2017 - sec filing Source text: (http://bit.ly/2vXMuCE) Further company coverage:

22 Aug 2017

BRIEF-Kura Oncology prices public offering of 7.70 mln common shares at $6.50 per share

* Kura oncology announces pricing of public offering of common stock

11 Aug 2017

BRIEF-Kura Oncology announces commencement of public offering of common stock

* Kura Oncology announces commencement of public offering of common stock

10 Aug 2017

BRIEF-Kura Oncology Q2 loss per share $0.40

* Kura Oncology reports second quarter 2017 financial results and provides update on Tipifarnib phase 2 study

08 Aug 2017

BRIEF-Kura Oncology ‍enters into collaboration agreement with Foundation Medicine ​

* Kura Oncology Inc - ‍entered into a collaboration agreement with Foundation Medicine, Inc.​

13 Jul 2017

Earnings vs. Estimates